Notable analyst calls this week: Meta, Boeing and Comcast among top picks

The S&P 500 (SP500) closed in the green on Friday, after investors saw a week full of earnings report from big tech firms including Meta, Apple, Alphabet and Amazon.

For the week, Nasdaq (COMP:IND) and Dow (DJI) fell marginally. Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week:

Meta grabs limelight following Q3 results

Oppenheimer downgraded Meta’s (META) rating to Perform from Outperform and removed its price target following Q3 results, and said risk/reward is "properly reflected" after the stock's plunge.

The research firm said the company's significant investment in its AI superintelligence unit, despite the unknown revenue opportunity, mirrors 2021/2022 Metaverse spending.

Citigroup maintained its Buy rating but lowered PT to $850 from $915, while acknowledging that the magnitude of investments is greater than what most expected.

Piper Sandler called the results "very impressive" and said the pressure on shares from the expense commentary for 2026 is a buying opportunity.

Bernstein also lowered PT by $30 to $870 on Meta, while BofA cut it by $90 to $810.

Fiserv in focus after Wall Street downgrades to Hold

Fiserv (FI) was in focus after Morgan Stanley, Goldman Sachs, and BTIG cut their recommendation on the stock to Hold-equivalent after the payment technology company's third quarter earnings release.

BTIG analysts Andrew Harte and Thomas Smith think "FI has lost its prestigious "high quality" label, as its 39-year streak of double-digit EPS growth been abruptly upended and numbers indicate the business is not a clear share-taker in either segment."

Morgan Stanley analyst ames Faucette downgraded the stock to Equal-weight from Overweight and slashed PT to $81 from $179.

"The work will take time, and so will rebuilding investor confidence," added Faucette.

Boeing downgraded on slower cash flow recovery

Boeing (BA) was downgraded to Hold from Buy by Deutsche Bank, as the analysts pointed to weaker free cash flow projections through 2027 and limited upside relative to current valuation.

Analysts led by Scott Deuschle said the downgrade reflects a recalibration of Boeing’s 2025-28 outlook, with free cash flow forecasts reduced to $2.1 billion for 2026, $6.0 billion for 2027 and $11.2 billion for 2028.

While Deuschle praised Boeing’s (BA) leadership for “making the right operational decisions,” particularly in the 737 and 787 programs, he cautioned that “the financial picture remains constrained by the burdens of the past.”

Comcast downgraded after third-quarter results

KeyBanc lowered rating on Comcast (CMCSA) to Sector weight from Overweight, citing a lack of catalysts following the company's third-quarter results.

KeyBanc pointed out that Comcast's broadband penetration rate has fallen for 14 consecutive quarters, and hence they need to see signs of stabilization before becoming more constructive on the company.

"Competitive concerns in broadband are likely to continue for the foreseeable future as telecom providers ramp fiber and FWA offerings over the next several years, where it's uncertain if and when Comcast will return to broadband subscriber growth," the brokerage said. KeyBanc currently does not have a price target for CMCSA.

Warner Bros. Discovery upgraded on potential bidding war

Warner Bros. Discovery (WBD) was upgraded to Buy from Hold at Argus on the potential for a bidding war. The upgrade comes after Warner Bros. announced last Monday that it was undertaking a strategic review of its assets.

"While there is no assurance a deal will actually get done, we like that WBD management has opened up the process to look at a range of alternatives to maximize the shareholder value of the WBD assets," said Argus analyst Joseph Bonner. He has a price target of $27 for the stock.

RBC upgraded Honeywell International (HON) to Outperform from Sector Perform, arguing that the U.S. industrial conglomerate is entering a “catalyst-rich phase” ahead of its planned breakup in the second half of 2026.

Jefferies and Wolfe Research both upgraded Edwards Lifesciences (EW) with Jefferies citing recent strong data for the SAPIEN M3 transcatheter mitral valve replacement (TMVR) and EVOQUE transcatheter tricuspid valve replacement (TTVR) systems, and Wolfe saying that risks it saw with the company are now unlikely to lead to negative results in the short term.